NASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis $18.63 -0.52 (-2.72%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$18.56▼$19.4150-Day Range$16.27▼$23.1452-Week Range$4.00▼$31.01Volume97,473 shsAverage Volume139,268 shsMarket Capitalization$280.64 millionP/E RatioN/ADividend YieldN/APrice Target$73.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Jasper Therapeutics alerts: Email Address Jasper Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside294.1% Upside$73.43 Price TargetShort InterestBearish16.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$21,744 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.16) to ($4.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector596th out of 910 stocksBiological Products, Except Diagnostic Industry94th out of 155 stocks 4.5 Analyst's Opinion Consensus RatingJasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJasper Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jasper Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.04% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Jasper Therapeutics has recently increased by 12.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JSPR. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Jasper Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,744.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jasper Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jasper Therapeutics are expected to grow in the coming year, from ($4.16) to ($4.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jasper Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Jasper Therapeutics Stock (NASDAQ:JSPR)Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Read More JSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JSPR Stock News HeadlinesSeptember 4 at 4:30 PM | globenewswire.comJasper Therapeutics to Present at Present at Upcoming September Investor ConferencesSeptember 1, 2024 | americanbankingnews.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $73.43 Consensus Price Target from AnalystsSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 28, 2024 | americanbankingnews.comEvercore ISI Reiterates "Outperform" Rating for Jasper Therapeutics (NASDAQ:JSPR)August 19, 2024 | markets.businessinsider.comJasper Therapeutics (JSPR) Gets a Buy from Stifel NicolausAugust 14, 2024 | markets.businessinsider.comBuy Rating for Jasper Therapeutics: Clinical Progress and Financial Stability Signal Strong PotentialAugust 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Jasper Therapeutics as Briquilimab Shows Promising Trial ProgressAugust 13, 2024 | globenewswire.comJasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. July 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)June 19, 2024 | globenewswire.comJasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of DirectorsJune 17, 2024 | globenewswire.comJasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology SummitJune 14, 2024 | globenewswire.comJasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid CongressMay 30, 2024 | globenewswire.comJasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024May 29, 2024 | globenewswire.comJasper Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 20, 2024 | markets.businessinsider.comBuy Rating for Jasper Therapeutics Amid Promising briquilimab Trials and Asthma Market PotentialMay 16, 2024 | markets.businessinsider.comBuy Rating on Jasper Therapeutics: High Hopes for Briquilimab’s Clinical TrialsMay 14, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsSee More Headlines Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JSPR CUSIPN/A CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$73.43 High Stock Price Target$90.00 Low Stock Price Target$60.00 Potential Upside/Downside+294.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($5.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.68% Return on Assets-56.10% Debt Debt-to-Equity RatioN/A Current Ratio10.80 Quick Ratio10.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book2.81Miscellaneous Outstanding Shares15,064,000Free Float14,657,000Market Cap$280.64 million OptionableOptionable Beta2.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ronald A. Martell (Age 62)President, CEO & Director Comp: $892.45kMr. Herbert C. Cross (Age 52)CFO & Corporate Secretary Dr. Luca Di Noto Ph.D.Senior Vice President of Technical OperationsMr. David Ku M.D.Vice President of Corporate Development, Portfolio Strategy & ManagementMr. Matthew FordVice President of Human ResourcesDr. Wendy Pang M.D.Ph.D., Senior Vice President of Research & Translational MedicineDr. Edwin Jonathan Tucker M.D. (Age 52)Chief Medical Officer Ms. Patricia CarlosSenior Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsDocGoNASDAQ:DCGOAgroFresh SolutionsNASDAQ:AGFSGreenLight BiosciencesNASDAQ:GRNAMomentusNASDAQ:MNTSARS PharmaceuticalsNASDAQ:SPRYView All CompetitorsInsiders & InstitutionsGreat Point Partners LLCSold 5,535 shares on 8/14/2024Ownership: 2.669%Ally Bridge Group NY LLCSold 71,329 shares on 8/14/2024Ownership: 1.451%American Century Companies Inc.Bought 3,032 shares on 8/8/2024Ownership: 0.094%Rhumbline AdvisersBought 13,231 shares on 8/1/2024Ownership: 0.088%Bank of New York Mellon CorpBought 32,579 shares on 7/26/2024Ownership: 0.216%View All Insider TransactionsView All Institutional Transactions JSPR Stock Analysis - Frequently Asked Questions How have JSPR shares performed this year? Jasper Therapeutics' stock was trading at $7.89 at the beginning of the year. Since then, JSPR shares have increased by 136.1% and is now trading at $18.63. View the best growth stocks for 2024 here. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) released its earnings results on Tuesday, August, 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.09) by $0.12. When did Jasper Therapeutics' stock split? Shares of Jasper Therapeutics reverse split before market open on Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Jasper Therapeutics' major shareholders? Jasper Therapeutics' top institutional shareholders include Great Point Partners LLC (2.67%), Ally Bridge Group NY LLC (1.45%), Bank of New York Mellon Corp (0.22%) and American Century Companies Inc. (0.09%). Insiders that own company stock include Velan Capital Investment Manag, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and Anna Louise French. View institutional ownership trends. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JSPR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts